Articles written by: Steven Goodstein

Juniper Networks Downgraded to Market Perform

Juniper Networks Downgraded to Market Perform

Juniper Networks (JNPR) received an investment-rating downgrade and price-target cut from BMO Capital Markets despite the network-technologies company’s late-Thursday report of better-than-expected Q2 results, as its guidance for Q3 came in below Street views. BMO now has an investment rating of market perform on Juniper’s shares, down from outperform. Its new price target from BMO is $27 per share, down […]

Kindred Biosciences Reports “Significantly Higher” Resolution Rates

Kindred Biosciences Reports “Significantly Higher” Resolution Rates

Kindred Biosciences (KIN) reported early Wednesday positive results from its pilot field effectiveness study of KIND-014 for the treatment of gastric ulcers in horses, with statistically significantly higher gastric ulcer resolution rates in all KIND-014 groups versus the placebo group. This study was a randomized, single-blind, placebo-controlled, dose-ranging study that enrolled 53 horses (40 horses in three KIND-014 groups with […]

Daktronics Shares Slide 2.5% Pre-Bell

Daktronics Shares Slide 2.5% Pre-Bell

Daktronics (DAKT) shares were down 2.5% pre-market Wednesday after the supplier of large-screen video displays reported it swung to a fiscal Q4 loss on declining sales, missing Street expectations. For the quarter ended April 28, the company reported a net loss per share of $0.09, compared to a gain of $0.02 a year earlier, and below the Street view for […]

Axon Enterprise Prices Offering of 4.3 Mln Shares at $53 Per Share

Axon Enterprise Prices Offering of 4.3 Mln Shares at $53 Per Share

Axon Enterprise (AAXN) said late Wednesday it priced an offering of 4.3 million common shares, 4 million of which will come from the company and 300,000 from CEO Patrick Smith, at $53 apiece. The company has granted underwriters a 30-day option to buy up to an additional 645,000 shares. Net proceeds will be used for working capital and other general […]

Loxo Oncology Gains More Than 14.5%

Loxo Oncology Gains More Than 14.5%

Loxo Oncology (LOXO) jumped more than 14.5% after the company said study investigators will present interim data from the ongoing Phase 1 clinical trial for LOXO-292 in oral and poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting. The submitted abstract utilized a January 2018 data cut-off date. The presentation at the ASCO Annual Meeting will use […]

Jounce Therapeutics Plunges More Than 27.5%

Jounce Therapeutics Plunges More Than 27.5%

Jounce Therapeutics (JNCE) slid more than 27.5% after the company said data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. It said it met its target enrollment for the Phase 1/2 ICONIC […]

ImmunoGen Reports Positive Findings

ImmunoGen Reports Positive Findings

ImmunoGen (IMGN) on Wednesday reported positive data from its FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha-positive ovarian cancer. The drugmaker said results from the cohort assessing mirvetuximab in combination with Avastin in patients with platinum-resistant disease will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which […]